Key Highlights

  • As of October 10, 2026, PROPEL-IPF, the Phase 2 idiopathic pulmonary fibrosis study of PIPE-791, had 25 countries authorized and more than 100 clinical sites open.
  • Patient dosing started during the first quarter of 2026, and the company holds full ownership of PIPE-791, its leading asset.
  • An April 2026 Phase 1b chronic pain result met its safety and tolerability objective, while pain relief compared with placebo was labeled exploratory.
  • PIPE-307, which J&J partnered, failed its efficacy endpoints in the Phase 2 VISTA multiple sclerosis trial in November 2025, and J&J is now assessing depression data.

PROPEL-IPF Reaches 25 Countries Across Global Sites

The 10-Q for Contineum Therapeutics (NASDAQ:CTNM), covering the quarter to September 30, 2026, went in on November 3, 2026. The company is developing drug candidates and has nothing approved for sale. Its leading program, PIPE-791, is in PROPEL-IPF, a worldwide Phase 2 study in idiopathic pulmonary fibrosis. Dosing started in early 2026, and by October 10, 2026 the trial held authorizations in 25 countries, including the European Union, the United Kingdom, Japan, Australia, Canada, South Korea and Taiwan, with more than 100 sites opened. The filing extract provides neither an enrollment count nor a readout date. Management also lists PIPE-307, partnered with J&J, as a second candidate, though the company describes its own future as dependent on PIPE-791 reaching approval for this disease.

Pain Results Remain Exploratory and a Partnered Asset Falters

PIPE-791 was also examined in a Phase 1b study of chronic osteoarthritis pain and chronic lower back pain, which finished enrolling in the fourth quarter of 2025. The company said in April 2026 that the study met its primary goal of safety and tolerability. Patients on PIPE-791 generally showed numerically larger pain relief than placebo, yet the filing emphasizes that the study was exploratory. PIPE-307, which J&J partnered, failed to hit its primary and secondary efficacy endpoints in multiple sclerosis in the Phase 2 VISTA trial. J&J is also reviewing MOONLIGHT-1 depression data and holds sole discretion over further development, so it could decide not to pursue PIPE-307 for depression or any other indication.

Reliance on One Asset, Funding Unknowns and Thin Trading

The filing states that the company depends heavily on PIPE-791, and that neither it nor J&J can submit a new drug application for several years, if ever. Drug Development is lengthy, costly and uncertain, and the filing warns that earlier results from the company or outside parties may not forecast later ones. Even after approval, a drug can only be sold in a given country once that country grants its own approval. The extract provided no cash, loss or runway figures, so funding needs cannot be gauged here. The company is an emerging growth company until the earliest of several triggers, with a final cutoff of December 31, 2029, and it is also a smaller reporting company. A small number of trades can move a stock like this, spreads can be wide, and quoted moves can reverse.

Where Things Stand

Reach across 25 countries is logistical rather than clinical proof. PROPEL-IPF's authorizations and more than 100 sites show how widely the company can recruit, not whether PIPE-791 works. Contineum Therapeutics (NASDAQ:CTNM) holds no approved products, a wholly owned lead candidate and a partnered program whose future now depends on J&J after a failed multiple sclerosis trial. Investors should track J&J's call on PIPE-307, enrollment updates for PROPEL-IPF and any financing in later filings.